| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/26/2008 | US7335354 Methods for the reduction of malignant tumors by an eosinophil/helminth therapy |
| 02/26/2008 | US7335353 Porcine cells comprising an adenovirus E3 gene region |
| 02/26/2008 | US7335351 Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme |
| 02/26/2008 | US7335350 Treating multiple sclerosis by orally administering an excipient and a RANTES polypeptide; preventing autoimmune and inflammatory diseases and bacterial and viral infections |
| 02/25/2008 | CA2586710A1 O-acetyltransferase from neisseria meningitidis, compositions and methods |
| 02/21/2008 | WO2008022349A2 Agents for blood-brain barrier delivery |
| 02/21/2008 | WO2008022302A2 Immunogenic pcpa polypeptides and uses thereof |
| 02/21/2008 | WO2008022146A2 Polymer-surfactant nanoparticles for sustained release of compounds |
| 02/21/2008 | WO2008021976A2 Anti-interferon alpha monoclonal antibodies and methods for use |
| 02/21/2008 | WO2008021959A2 Influenza hemagglutinin and neuraminidase variants |
| 02/21/2008 | WO2008021873A2 Stabilized liquid preservative compositions |
| 02/21/2008 | WO2008021542A2 Lysine acteylation sites |
| 02/21/2008 | WO2008021475A2 Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
| 02/21/2008 | WO2008021415A2 Glycan data mining system |
| 02/21/2008 | WO2008021353A2 Composition and method for controlling hepatitis c virus infection |
| 02/21/2008 | WO2008021295A2 Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1 |
| 02/21/2008 | WO2008021263A2 Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof |
| 02/21/2008 | WO2008021250A2 Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins |
| 02/21/2008 | WO2008021092A2 Trypanosome microsome system and uses thereof |
| 02/21/2008 | WO2008021076A2 Protein matrix vaccines and methods of making and administering such vaccines |
| 02/21/2008 | WO2008020656A1 A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| 02/21/2008 | WO2008020596A2 Treating or preventing cancers over-expressing reg4 or kiaa0101 |
| 02/21/2008 | WO2008020586A1 Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| 02/21/2008 | WO2008020322A2 Combination vaccines with 1-hydroxy-2-phenoxyethane preservative |
| 02/21/2008 | WO2008020108A1 Peptides which are immunogenic in relation to the genuses listeria and mycobacterium, antibodies and uses of these |
| 02/21/2008 | WO2008019888A2 Pax2 and pax8 as targets for immunologic and molecular tumour treatment strategies |
| 02/21/2008 | WO2007140410A9 Low-density lipoprotein receptor 6 (lrp6) as a mammary stem cell marker and related methods |
| 02/21/2008 | WO2007138143A3 Alpha anticholine kinase monoclonal antibodies and their use in analytical techniques for the diagnosis of cancer and the preparation of medicinal products |
| 02/21/2008 | WO2007126887A3 Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use |
| 02/21/2008 | WO2007124308A3 Methods and compositions for modulation of blood-neural barrier |
| 02/21/2008 | WO2007123667A3 Membrane-permeant peptide complexes for treatment of sepsis |
| 02/21/2008 | WO2007120999A3 Chelating monomers and polymers |
| 02/21/2008 | WO2007110698A3 Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors |
| 02/21/2008 | WO2007109221A3 Methods for reducing protein aggregation |
| 02/21/2008 | WO2007108903A3 Campylobacter vaccines and methods of use |
| 02/21/2008 | WO2007079312A3 Compositions and methods for treating actin-mediated medical conditions |
| 02/21/2008 | WO2007014238A8 Single dose use of cd20-specific binding molecules |
| 02/21/2008 | WO2007011941A9 Human anti-b7rp1 neutralizing antibodies |
| 02/21/2008 | WO2006136084A8 Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses |
| 02/21/2008 | WO2006053439A9 Hcv f protein and uses thereof |
| 02/21/2008 | WO2006047298A3 Eph receptor tumor biomarkers |
| 02/21/2008 | WO2005016247A3 Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars |
| 02/21/2008 | US20080045701 Human Monoclonal Antibody Having Fat-Reducing Effect |
| 02/21/2008 | US20080045698 Mammalian receptor proteins; related reagents and methods |
| 02/21/2008 | US20080045474 Method for treatment of invasive cells |
| 02/21/2008 | US20080045444 Compositions and methods for treating cardiovascular disease and myocardial infarction with dipeptidyl peptidase inhibitors or b type natriuretic peptide analogues resistant to prolyl-specific dipeptidyl degradation |
| 02/21/2008 | US20080044828 CUDR as biomarker for cancer progression and therapeutic response |
| 02/21/2008 | US20080044806 diagnostic method and vaccine using a composition comprising truncated r47 protein and truncated r56 protein; reducing HIV viral loads |
| 02/21/2008 | US20080044452 Drug delivery system for treatment of transitional cell carcinoma |
| 02/21/2008 | US20080044441 Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| 02/21/2008 | US20080044440 Vaccine Formulated For Administration To Mucosa Of The Lungs |
| 02/21/2008 | US20080044439 Compositions and Methods for Preventing and Treating Skin and Hair Conditions |
| 02/21/2008 | US20080044438 Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
| 02/21/2008 | US20080044437 Encapsidation System for Production of Recombinant Virus-Like Particles |
| 02/21/2008 | US20080044435 Tat-Based Tolerogen Compositions and Methods of Making and Using Same |
| 02/21/2008 | US20080044433 Epitopes of hepatitis C virus |
| 02/21/2008 | US20080044432 Mammalian receptor proteins; related reagents and methods |
| 02/21/2008 | US20080044431 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms |
| 02/21/2008 | US20080044430 Agent for Stimulating the Production of a Blood Coagulation Factor VIII |
| 02/21/2008 | US20080044429 Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
| 02/21/2008 | US20080044428 Glycosylphosphatidylinositol Glycan Signalling Via Integrins Functioning as Glycan Specific Receptors |
| 02/21/2008 | US20080044427 Plant virus |
| 02/21/2008 | US20080044426 Novel Atypical Pneumonia-Causing Virus |
| 02/21/2008 | US20080044425 Polypeptides having phospholipase a2 activity |
| 02/21/2008 | US20080044424 Antagonists of protease activated receptor-1 (par1) |
| 02/21/2008 | US20080044423 Compounds |
| 02/21/2008 | US20080044422 CNGH0010 Specific Polynucleotides, Polypeptides, Antibodies, Compositions, Methods and Uses |
| 02/21/2008 | US20080044421 Methods of using death receptor ligands and CD20 antibodies |
| 02/21/2008 | US20080044420 Anti-IL-13 antibodies, compositions, methods and uses |
| 02/21/2008 | US20080044419 Treatment of T Cell Mediated Diseases by Inhibition of Fgfr3 |
| 02/21/2008 | US20080044418 Tumor Antigens and Uses Thereof |
| 02/21/2008 | US20080044417 Cancer, autoimmune and inflammatory disease, vaccines; binds to the extracellular domain of native human Fc gamma RIIB with greater affinity than to the extracellular domain of native human Fc gamma RIIA |
| 02/21/2008 | US20080044416 Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
| 02/21/2008 | US20080044415 Hepatocyte growth factor receptor antagonists and uses thereof |
| 02/21/2008 | US20080044413 EphA2 BiTE molecules and uses thereof |
| 02/21/2008 | US20080044412 Single-Domain Antibody Strengthening Fusion Protein Vh-Ldp-Ae |
| 02/21/2008 | US20080044411 Human glp-1 mimetibodies, compositions, methods and uses |
| 02/21/2008 | US20080044410 Immunoglobulin against growth differentiation factor -8 (GDF-8) for use in the prevention and treatment of bone, muscular, nervous system and obesity; muscle enhancement; disorders of insulin metabolism |
| 02/21/2008 | US20080044409 Inflammatory mediator antagonists |
| 02/21/2008 | US20080044408 Diagnosis, therapy of cancerous diseases; using cancerous disease modifying antibodies |
| 02/21/2008 | US20080044407 Mage-a3/hpv 16 peptide vaccines for head and neck cancer |
| 02/21/2008 | US20080044405 Noble metal complex-mediated immunosuppression |
| 02/21/2008 | US20080044404 Annexin V for Preventing Atherothrombosis and Plaque Rupture |
| 02/21/2008 | US20080044382 Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| 02/21/2008 | US20080044377 Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine |
| 02/21/2008 | US20080044356 Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| 02/21/2008 | CA2697742A1 Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy |
| 02/21/2008 | CA2661296A1 Development of dengue virus vaccine components |
| 02/21/2008 | CA2661023A1 Prlr-specific antibody and uses thereof |
| 02/21/2008 | CA2660830A1 Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1 |
| 02/21/2008 | CA2660743A1 Immunogenic pcpa polypeptides and uses thereof |
| 02/21/2008 | CA2660516A1 Treating or preventing cancers over-expressing reg4 or kiaa0101 |
| 02/21/2008 | CA2660463A1 Antibodies to il-17a |
| 02/21/2008 | CA2660373A1 Methods and compositions for needleless delivery of particles |
| 02/21/2008 | CA2660022A1 Protein matrix vaccines and methods of making and administering such vaccines |
| 02/21/2008 | CA2660010A1 Trypanosome microsome system and uses thereof |
| 02/21/2008 | CA2659552A1 Immunogens from uropathogenic escherichia coli |
| 02/21/2008 | CA2659267A1 Influenza hemagglutinin and neuraminidase variants |
| 02/21/2008 | CA2658557A1 Optimized antibodies that target cd19 |
| 02/21/2008 | CA2658050A1 Diagnosis and treatment of cancer using anti-desmoglein 3 antibodies |